Accretion Nutraveda's First Year Post-IPO: Profit Soars 102%, Revenue Doubles

Accretion Nutraveda Ltd has reported strong financial results for its first full year as a listed company. The company posted standalone total revenue of ₹33.72 Crores and a net profit of ₹5.07 Crores for the year ending March 31, 2026. Earnings Per Share (EPS) stood at ₹9.35 for the period.

Full Year Results Show Strong Growth

Accretion Nutraveda's standalone revenue for the fiscal year ended March 31, 2026, surged by 110.62% to ₹33.72 Crores, up from ₹1,600.80 Lakhs in the previous year. Net profit also climbed significantly, rising 102.66% to ₹5.07 Crores from ₹250.09 Lakhs year-over-year. The company's annual results received an unmodified opinion from its statutory auditors.

Key Milestones Achieved Post-IPO

This performance marks a significant achievement in Accretion Nutraveda's debut year as a publicly traded entity on the BSE SME platform. The substantial growth in both revenue and profit suggests effective use of funds raised during its Initial Public Offering (IPO) and a positive market reception.

About Accretion Nutraveda and Its IPO

Accretion Nutraveda operates in the nutraceutical and health supplement industry, manufacturing vitamins, minerals, and herbal supplements. The company raised ₹10.64 Crores through its IPO, with shares priced at ₹36 each. The IPO funds were earmarked for acquiring new machinery and bolstering working capital. The company's shares began trading on the BSE SME platform on February 4, 2026.

Governance Concerns and Financial Trends

Investors will be closely monitoring corporate governance following the simultaneous resignation of two independent directors, Mr. Arun Dash and Mr. Mahipal Singh Chouhan, on May 8, 2026. This departure raises questions about board stability.

Additionally, the company's long-term borrowings increased from ₹246.05 Lakhs in FY25 to ₹378.15 Lakhs in FY26. While revenues grew robustly, total expenses increased by 113.96%, slightly outpacing the 110.62% revenue growth.

Market Context and Peers

Finding direct listed peers for a specialized nutraceutical company on the BSE SME platform like Accretion Nutraveda is difficult. Larger companies such as Piramal Pharma Ltd and Emami Ltd operate in broader healthcare and FMCG sectors, offering limited direct comparisons. The company's post-IPO growth will be benchmarked against other small and medium enterprises (SMEs) that have recently listed.

Key Financial Figures

• Standalone Total Revenue Growth (FY25 to FY26): 110.62%
• Standalone Net Profit Growth (FY25 to FY26): 102.66%
• Long-Term Borrowings Increase (FY25 to FY26): Approximately 53.7% (from ₹246.05 Lakhs to ₹378.15 Lakhs)

Looking Ahead: What Investors Should Watch

Investors will want to see the company's strategy and management's commentary regarding the director resignations. Key factors to track include:

• Sustained revenue growth and efficient expense management in future financial results.
• Progress on the utilization of IPO funds for machinery and working capital.
• Any new product launches or market expansion plans.
• Announcements about new board appointments to fill the vacant independent director positions.